CEBPA methylation as a prognostic biomarker in patients with de novo acute myeloid leukemia

Hypermethylation of the distal CEBPA promoter region has been reported to result in the downregulation of CEBPA expression in several malignancies. However, the clinical implication of CEBPA hypermethylation in acute myeloid leukemia (AML) remains unclear. To investigate the correlation between CEBP...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Leukemia 2011-01, Vol.25 (1), p.32-40
Hauptverfasser:	Lin, T-C, Hou, H-A, Chou, W-C, Ou, D-L, Yu, S-L, Tien, H-F, Lin, L-I
Format:	Artikel
Sprache:	eng
Schlagworte:	692/53/2422 692/699/67/1990/283/1897 Analysis Biological and medical sciences Biomarkers Bone marrow Cancer Research CCAAT-Enhancer-Binding Proteins - genetics Chemotherapy Critical Care Medicine Disease-Free Survival DNA Methylation Drug dosages Epigenetics Genetic aspects Granulocytes Hematologic and hematopoietic diseases Hematology Hospitals Humans Intensive Internal Medicine Leukemia Leukemia, Myeloid, Acute - drug therapy Leukemia, Myeloid, Acute - genetics Leukemia, Myeloid, Acute - mortality Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Medical laboratories Medical prognosis Medical sciences Medicine Medicine & Public Health Methylation Mutation Nuclear Proteins - genetics Oncology original-article Physiological aspects Prognosis Promoter Regions, Genetic Remission (Medicine) Translocation, Genetic Tumor markers
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!